The purpose of this study is to test the safety of TAEK-VAC-HerBy vaccine given intravenously to people with advanced cancer. The vaccine is manufactured by Bavarian Nordic (BN) and is known as TAEK-VAC-HerBy. The vaccine tested in this study is made up of a virus called Modified Vaccinia Ankara-BN (MVA-BN) virus. The virus does not have the ability to grow in hman cells, instead it releases an immune response without the risk of viral infection. The goal is to teach the immune system to kill the tumor cells that express the Brachyury protein and the HER2 protein to help stop tumor cell growth and metatisis.